Stockscreener 앱 받기
59.43
0.35%
0.21
시간 외 거래:
59.43
전일 마감가:
$59.22
열려 있는:
$59.22
하루 거래량:
409.66K
Relative Volume:
0.79
시가총액:
$3.65B
수익:
$112.53M
순이익/손실:
$-258.91M
주가수익비율:
-13.73
EPS:
-4.33
순현금흐름:
$-124.42M
1주 성능:
+2.86%
1개월 성능:
+6.16%
6개월 성능:
+23.27%
1년 성능:
+34.73%
1일 변동 폭
$58.80
$60.69
1주일 범위
$55.14
$60.69
52주 변동 폭
$35.17
$68.58
Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile
명칭
Rhythm Pharmaceuticals Inc
전화
857-264-4280
주소
222 BERKELEY STREET, BOSTON, MA
RYTM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RYTM
Rhythm Pharmaceuticals Inc
|
59.43 | 3.65B | 112.53M | -258.91M | -124.42M | -4.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-02 | 개시 | Jefferies | Buy |
| 2024-12-20 | 개시 | Oppenheimer | Outperform |
| 2024-10-21 | 개시 | Guggenheim | Buy |
| 2024-09-18 | 개시 | H.C. Wainwright | Buy |
| 2024-09-17 | 개시 | JMP Securities | Mkt Outperform |
| 2024-05-08 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-12-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-08-01 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-01-18 | 재개 | Canaccord Genuity | Buy |
| 2022-08-08 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-08-05 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2022-06-17 | 재확인 | Needham | Buy |
| 2022-03-02 | 재개 | Stifel | Buy |
| 2022-02-17 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2021-12-08 | 개시 | Wells Fargo | Overweight |
| 2021-11-19 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-14 | 재개 | Goldman | Neutral |
| 2021-08-04 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2021-08-04 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2020-11-30 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-01-08 | 개시 | Goldman | Sell |
| 2019-07-12 | 업그레이드 | Stifel | Hold → Buy |
| 2019-07-08 | 개시 | Canaccord Genuity | Buy |
| 2019-03-13 | 개시 | Ladenburg Thalmann | Buy |
| 2018-09-07 | 재개 | Morgan Stanley | Overweight |
| 2018-06-25 | 재확인 | Needham | Buy |
| 2018-06-15 | 재확인 | Needham | Buy |
| 2017-10-30 | 개시 | BofA/Merrill | Buy |
| 2017-10-30 | 개시 | Needham | Buy |
모두보기
Rhythm Pharmaceuticals Inc 주식(RYTM)의 최신 뉴스
Nisa Investment Advisors LLC Sells 64,955 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Shares Sold by Nisa Investment Advisors LLC - Defense World
Wall Street Analysts Think Rhythm Pharmaceuticals (RYTM) Could Surge 26.36%: Read This Before Placing a Bet - Yahoo Finance
How To Trade (RYTM) - Stock Traders Daily
Soligenix (NASDAQ:SNGX) & Rhythm Pharmaceuticals (NASDAQ:RYTM) Head to Head Contrast - Defense World
Rhythm Pharmaceuticals (RYTM) Soars 5.5%: Is Further Upside Left in the Stock? - MSN
Earnings call transcript: Rhythm Pharmaceuticals Q3 2024 sees growth - MSN
Rhythm Pharmaceuticals (NASDAQ:RYTM) Sees Large Volume IncreaseStill a Buy? - MarketBeat
Exploring High Growth Tech Stocks in January 2025 - Simply Wall St
Earnings call transcript: Rhythm Pharmaceuticals Q3 2024 sees growth By Investing.com - Investing.com Canada
Subdued Growth No Barrier To Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Price - Simply Wall St
JPMorgan Chase & Co. Sells 58,554 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World
Long Term Trading Analysis for (RYTM) - Stock Traders Daily
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives $68.09 Average Target Price from Analysts - Defense World
Head to Head Review: ABVC BioPharma (NASDAQ:ABVC) vs. Rhythm Pharmaceuticals (NASDAQ:RYTM) - Defense World
Rhythm gets FDA approval for Imcivree for toddlers - MSN
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Harbor Capital Advisors Inc. Sells 11,116 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
Rhythm Pharmaceuticals (NASDAQ: RYTM) Reports Strong Growth in Revenue and Clinical Development Initiatives - Defense World
Rhythm Pharmaceuticals price target raised to $60 from $58 at BofA - MSN
Rhythm Pharmaceuticals, Inc. Provides Preliminary Revenue Guidance for the Fourth Quarter and Full Year of 2024 - Marketscreener.com
Rhythm Pharmaceuticals Reports Growth and Expands Pipeline - TipRanks
Rhythm Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2024 Net Product Revenues, Pipeline Advancements and Upcoming Milestones - The Manila Times
Rhythm Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2024 Net Product - The Bakersfield Californian
Rhythm Pharmaceuticals Announces Preliminary Fourth Quarter - GlobeNewswire
Rhythm Pharmaceuticals Delivers Record $130M Revenue in 2024, Q4 Sales Surge 26% - StockTitan
Principal Financial Group Inc. Has $1.71 Million Stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World
Principal Financial Group Inc. Buys 23,054 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
Rhythm Pharmaceuticals (NASDAQ:RYTM) Now Covered by Analysts at Jefferies Financial Group - Defense World
Jefferies starts Rhythm Pharmaceuticals with Buy on obesity potential - Yahoo Finance
Jefferies Financial Group Begins Coverage on Rhythm Pharmaceuticals (NASDAQ:RYTM) - MarketBeat
Where are the Opportunities in (RYTM) - Stock Traders Daily
Stifel Financial Corp Has $1.04 Million Stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World
Rhythm Pharmaceuticals (NASDAQ:RYTM) Receives Market Outperform Rating from JMP Securities - Defense World
Rhythm Pharmaceuticals (NASDAQ:RYTM) Receives Buy Rating from HC Wainwright - Defense World
Rhythm Pharmaceuticals (NASDAQ:RYTM) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
Rhythm Pharmaceuticals (NASDAQ:RYTM) Given "Market Outperform" Rating at JMP Securities - MarketBeat
Rhythm Pharmaceuticals' (NASDAQ:RYTM) investors will be pleased with their incredible 370% return over the last three years - Yahoo Finance
Rhythm Pharmaceuticals' (RYTM) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
FDA nod for Rhythm Pharma’s Imcivree - The Pharma Letter
Analysts Set Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Price Target at $64.67 - Defense World
Franklin Resources Inc. Purchases 26,739 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
Barclays PLC Buys 47,166 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
Rhythm Pharma Modifies Trials of Genetic Obesity Medicine; Shares Drop - Marketscreener.com
Oppenheimer Initiates Coverage of Rhythm Pharmaceuticals (RYTM) with Outperform Recommendation - MSN
FDA Expands Rhythm Pharma Obesity Drug Approval to Younger Children - MarketWatch
Rhythm Pharmaceuticals' Obesity Treatments Target Less Crowded Space, Analyst Sees Long-Term Potential - Benzinga
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® - GlobeNewswire
Rhythm Pharma's IMCIVREE Wins FDA Approval for Rare Obesity Treatment in Young Children - StockTitan
Rhythm Pharmaceuticals (NASDAQ:RYTM) Now Covered by Oppenheimer - MarketBeat
Forecasting The Future: 14 Analyst Projections For Rhythm Pharmaceuticals - Benzinga
Rhythm Pharmaceuticals Inc (RYTM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.95%
2.39%
자본화:
|
볼륨(24시간):